{"created":"2023-06-20T15:58:40.757064+00:00","id":16210,"links":{},"metadata":{"_buckets":{"deposit":"fe660bfb-f319-4b72-a23d-39c4ffe2456b"},"_deposit":{"created_by":22,"id":"16210","owners":[22],"pid":{"revision_id":0,"type":"depid","value":"16210"},"status":"published"},"_oai":{"id":"oai:redcross.repo.nii.ac.jp:00016210","sets":["100:90:584"]},"author_link":["60416"],"item_10002_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2019-12","bibliographicIssueDateType":"Issued"},"bibliographicPageEnd":"28","bibliographicPageStart":"13","bibliographicVolumeNumber":"40","bibliographic_titles":[{"bibliographic_title":"京都第二赤十字病院医学雑誌  "},{"bibliographic_title":"Medical journal of Kyoto Second Red Cross Hospital","bibliographic_titleLang":"en"}]}]},"item_10002_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":" 進行期非小細胞肺癌における細胞障害性抗がん剤の全生存（OS）延長効果が1995 年に発表された際，生存期間中央値は約6 ヶ月と短期間であった．その後，①細胞障害性抗がん剤，②血管新生阻害薬，③ドライバー遺伝子変異，④免疫チェックポイント阻害薬，⑤複合免疫療法などの進歩とともに，OS は劇的に延長した．\n 細胞障害性抗がん剤は，第3 世代抗がん剤の出現でOS が延長し，更に非扁平上皮非小細胞肺癌ではpemetrexed が有用である．\n 血管新生阻害薬は，1 次治療で非扁平上皮非小細胞肺癌へのbevacizumab 併用が，2 次治療ではdocetaxel へのramucirumab 上乗せがOS を延長した．\n ドライバー遺伝子変異はEGFR 遺伝子変異，ALK 遺伝子転座，ROS1 遺伝子転座，BRAF 遺伝子変異が臨床応用された．\n 免疫チェックポイント阻害薬は，nivolumab, pembrolizumab, atezolizumab が2 次治療以降でdocetaxelに対する優越性を示し，PD-L1 発現率が50％ 以上の症例では1 次治療でのpembrolizumab 単剤がプラチナ併用療法を凌駕した．その後，1 次治療で複合免疫療法が更に良好な成績を収めた．","subitem_description_type":"Abstract"}]},"item_10002_publisher_8":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"京都第二赤十字病院"}]},"item_10002_source_id_11":{"attribute_name":"書誌レコードID","attribute_value_mlt":[{}]},"item_10002_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"0389-4908 ","subitem_source_identifier_type":"ISSN"}]},"item_10002_version_type_20":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"竹田, 隆之"}],"nameIdentifiers":[{},{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2020-01-06"}],"displaytype":"simple","filename":"MJKSRCH40_13.pdf","filesize":[{"value":"853.0 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"kyo2_000110","url":"https://redcross.repo.nii.ac.jp/record/16210/files/MJKSRCH40_13.pdf"},"version_id":"63dd69ed-5235-41c0-928f-c2f017f5c527"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"血管新生阻害薬","subitem_subject_scheme":"Other"},{"subitem_subject":"ドライバー遺伝子変異","subitem_subject_scheme":"Other"},{"subitem_subject":"非小細胞肺癌","subitem_subject_scheme":"Other"},{"subitem_subject":"複合免疫療法","subitem_subject_scheme":"Other"},{"subitem_subject":"免疫チェック ポイント阻害薬","subitem_subject_scheme":"Other"},{"subitem_subject":"anti-angiogenic therapy","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"chemo-immunotherapy","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"immune checkpoint inhibitor","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"nonsmall- cell lung cancer","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"oncogenic driver mutation","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"departmental bulletin paper","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"非小細胞肺癌における薬物療法の進歩","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"非小細胞肺癌における薬物療法の進歩"},{"subitem_title":"Recent advances in the systemic treatment of non-small-cell lung cancer","subitem_title_language":"en"}]},"item_type_id":"10002","owner":"22","path":["584"],"pubdate":{"attribute_name":"公開日","attribute_value":"2020-01-06"},"publish_date":"2020-01-06","publish_status":"0","recid":"16210","relation_version_is_last":true,"title":["非小細胞肺癌における薬物療法の進歩"],"weko_creator_id":"22","weko_shared_id":-1},"updated":"2023-06-20T18:30:43.864576+00:00"}